The Environmental Protection Agency (EPA) has taken a significant step towards addressing the growing concern over microplastics and pharmaceuticals in drinking water. This move, which could lead to new regulations and limits on these substances, is a response to public health worries and pressure from environmental groups. The EPA's decision to include microplastics and pharmaceuticals on its Contaminant Candidate List is a crucial first step, but it also highlights the complex challenges in regulating plastic pollution. The agency's actions are particularly notable given the political dynamics surrounding the EPA and the influence of figures like Health Secretary Robert F. Kennedy Jr. and his MAHA movement.
The Contaminant Candidate List, which is updated every five years, identifies contaminants in drinking water not regulated under the Safe Drinking Water Act. The latest draft list includes microplastics, pharmaceuticals, PFAS, and disinfection byproducts, as well as 75 chemicals and nine microbes that may be found in drinking water. This comprehensive approach is a positive development, but it also underscores the need for further action to address the full scope of plastic pollution.
One of the key challenges in regulating microplastics is the lack of clear evidence on their human health impacts. While studies have found microplastics in various human tissues, including the heart, brain, and testicles, the long-term health consequences remain uncertain. This uncertainty is a significant barrier to setting regulatory limits, as it makes it difficult to justify the costs and potential economic impacts of such regulations.
The EPA's decision to prioritize research and monitoring rather than immediate regulation is a pragmatic approach. However, it also raises questions about the agency's commitment to addressing the plastic pollution crisis. Erik Olson, a senior attorney at the Natural Resources Defense Council, suggests that the EPA's process is often a long and fruitless journey, with little chance of regulatory action. This perception is not entirely unfounded, given the EPA's history of inaction on other contaminants.
The influence of political figures like Kennedy and the MAHA movement is a critical aspect of this story. Kennedy's campaign and efforts to measure and remove microplastics from the human body, such as the STOMP initiative, demonstrate a strong commitment to addressing plastic pollution. However, the EPA's tepid response to pesticide regulation and the executive order supporting glyphosate production suggest that political considerations can complicate environmental regulation.
The EPA's decision to include microplastics and pharmaceuticals on the Contaminant Candidate List is a necessary and positive step. However, it is just the beginning of a long and complex process. To make a meaningful impact on plastic pollution, the EPA must address the underlying issues of plastic production and consumption, and it must do so in a way that balances environmental protection with economic and political realities. The challenge is to turn this draft list into a tangible regulatory framework that protects public health and the environment without stifling innovation and economic growth.
